AbbVie Inc. is a Biopharmaceutical company with $56.3B in 2024 revenue and 50K employees worldwide. AbbVie Inc. Occupies a unique position in American business history as a company created specifically to extract maximum value from a single extraordinarily productive drug franchise, then forced to reinvent itself before that franchise's commercial dominance faded. The story of AbbVie is in many ways the story of modern biopharmaceutical capitalism: the identification of a breakthrough biological mechanism, the conversion of that mechanism into a commercial juggernaut through aggressive clinical development and marketing, the accumulation of profits sufficient to fund the next generation of innovation, and the execution — under extraordinary pressure — of a transition that most Wall Street analysts initially doubted. Headquartered in North Chicago, Illinois, roughly 35 miles north of downtown Chicago on a campus that sits within sight of Lake Michigan, AbbVie is deeply embedded in the broader Chicago-area business community. The company's executive leadership has remained relatively stable since the spin-off, with Richard Gonzalez serving continuously as Chairman and CEO — an unusual tenure by the revolving-door standards of large-cap pharmaceutical executives. This leadership continuity has allowed AbbVie to pursue a consistent long-term strategy even as quarterly financial results experienced significant volatility during the Humira biosimilar transition period. The company's employee base of approximately 50,000 spans scientific research functions in Lake County, Illinois, San Francisco's Bay Area, and other global innovation hubs; manufacturing operations across the United States, Ireland, Germany, and Singapore; and commercial operations in virtually every developed pharmaceutical market. This global footprint, built through a combination of organic growth and acquisition integration, gives AbbVie the operational capacity to commercialize new drugs across dozens of markets simultaneously — a capability that distinguishes large-cap pharmaceutical companies from the biotechnology startups that often make the initial scientific discoveries.